FLASCO
- FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma April 23, 2024On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
- FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS April 23, 2024On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis company) for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. Lutetium Lu 177 dotatate received approvalExternal Link Disclaimer for this...
- FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer April 22, 2024On April 22, 2024, the Food and Drug Administration approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
- FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer April 18, 2024On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
- Strategies for Reducing Health Disparities April 8, 2024A major goal of public health is to reduce health disparities. The programs described in the MMWR Supplement, Strategies for Reducing Health Disparities—Selected CDC-Sponsored Interventions, United States, 2016, are examples of CDC-sponsored initiatives that address health disparities with the goal of advancing health equity.
- MIPS Extreme and Uncontrollable Circumstances Exception Application Reopened Following Change Healthcare Cyberattack March 28, 2024CMS reopened the Merit-based Incentive Payment System (MIPS) Extreme & Uncontrollable Circumstances (EUC) Exception Application for 2023 due to the Change Healthcare cyberattack. Clinicians who have not yet submitted their 2023 MIPS data to CMS, can submit hardship exemption requests for one or more performance categories until April 15, 2024, at 8 pm ET. The...
- ASCO Issues New Guidance on Cannabis and Cannabinoid Use in Adults With Cancer March 28, 2024Many Americans use cannabis and cannabinoids. In response to this reality, ASCO has issued a guideline for clinicians, adults with cancer, caregivers, and researchers on their medical use. The recommendations cover all cancer types and address products ranging from synthetic cannabinoids to full-spectrum cannabis.
- ASCO Congratulates 2024 Special Awards Recipients March 28, 2024ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2024 ASCO Annual Meeting.
- Breast Cancer Rapid Recommendation Update on Capivasertib-Fulvestrant March 26, 2024On February 6, a rapid recommendation update on Capivasertib-Fulvestrant was published. The rapid update has implications for two guidelines: Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancers and Biomarkers for Systemic Therapy in Metastatic Breast Cancer.
- Stage IV NSCLC Living Guidelines Updated March 26, 2024On February 28, the Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations Comprehensive Living Guideline Update published. Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. An algorithm, recommendations table, slides, podcast, and pocketcard accompany the guideline. In addition, the Therapy for Stage IV...